|
Online CME Activity
The Pharmacist’s Role in Epilepsy Management: Current Treatment Issues and Future Trends
|
NOTE: Although this activity is no longer certified for credit, we believe that it contains important information and hope you’ll review, print or email it to a colleague.
The Pharmacist’s Role in Epilepsy Management: Current Treatment Issues and Future Trends
0.50 AMA PRA Category 1 Credits™, 0.50 ACPE
Learning Objectives
Describe the adverse events that may follow generic substitution of AEDs, and the role of the pharmacist in encouraging reporting of these adverse events to the FDA.
Discuss the emerging clinical data on the benefits of including pharmacists as part of collaborative drug therapy management in epilepsy clinics
Accreditation
This educational program is conceived and credited in accordance with ACCME's Essential Areas and Policies, including the 2004 Updated Standards for Commercial Support. Pri-Med faculty hail from a variety of institutions and participate in content development, along with Pri-Med Institute's Advisory Boards and its expert review partners, the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute. All final decisions about program content are the responsibility of Pri-Med Institute.
| Credits |
Type |
Accreditation Statement |
Designation Statement |
| 0.50 |
AMA PRA Category 1 Credits™ |
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. |
Pri-Med Institute designates this educational activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
| 0.50 |
ACPE
 |
Pri-Med Institute is accredited by the American Council on Pharmacy Education as a provider of continuing pharmacy education. |
Pri-Med Institute designates this continuing education activity for .5 contact hours of continuing pharmacy education. |
Faculty and Editorial Board
Written By:
Timothy E. Welty, MA, PharmD, FCCP, BCPS, Professor and Chair, Department of Pharmacy Practice, School of Pharmacy, University of Kansas
Edited By:
Christopher Drury, MA
Financial Disclosure Statement(s)
Dr. Welty has received consulting fees from UCB Pharma and GlaxoSmithKline. He serves on the Access to Care Task Force for the American Epilepsy Society and is part of the core working group that is designing a trial on generic substitution for a NIH grant; he currently has a planning grant from NIH to work on this project.
The content collaborators at the American Epilepsy Society has no financial relationships to disclose.
The content collaborators at Pri-Med Institute have no financial relationships to disclose.
Mr Drury has no financial relationships to disclose.
Commercial Support:
GlaxoSmithKline and UCB, Inc.
Instructions for Obtaining Credit:
Complete this activity. Answer the questions in the attached posttest and evaluation. Click on "claim credit" and follow the instructions to print out the credit certificate.
Computer System Requirements:
Internet Explorer (version 5.5 and above) is the recommended browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A minimum screen resolution setting of 800 x 600 is recommended. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.
Disclaimer
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, or M|C Communications, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
|
|
|